Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy.

NCT03756298 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT03756298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03756298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for TNBC With Residual Invasive Cancer After Neoadjuvant Chemotherapy.
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 15, 2019
Completion date
December 31, 2027
Enrollment
284 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast cancer